BioPharma Dive – AI / Data

Novartis targets Xolair successor in buyout of startup Excellergy

Published

2 weeks ago

on

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine. 

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version